Orantinib

DB12072InvestigationalSmall molecule

Orantinib has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Kidney Cancer, Gastric Cancer, and Prostate Cancer, among others.

Mechanism: Pharmacologically active on Fibroblast growth factor receptor and Vascular endothelial growth factor receptor 2
Curator reviewed
Formula / weight: C₁₈H₁₈N₂O₃ · 310.3471 g/mol (avg)
Code names: NSC-702827 · SU-6668 · TSU-68

Resolves to

Compound

UNII9RL37ZZ665CAS252916-29-3ChEMBLCHEMBL274654PubChem5329099

Structure

InChIKeyNHFDRBXTEDBWCZ-ZROIWOOFSA-NSMILESCC1=C(CCC(O)=O)C(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12

Targets

P35968KDRQ96GD4AURKBP11362FGFR1O14965AURKAP37231PPARG

What you can answer from here — as of June 15, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Orantinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account